Your browser is no longer supported. Please, upgrade your browser.
VRCA Verrica Pharmaceuticals Inc. daily Stock Chart
Verrica Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own48.92% Shs Outstand24.96M Perf Week-12.00%
Market Cap208.56M Forward P/E- EPS next Y-2.01 Insider Trans0.00% Shs Float9.85M Perf Month-22.67%
Income-30.60M PEG- EPS next Q-0.45 Inst Own35.00% Short Float8.43% Perf Quarter-20.29%
Sales- P/S- EPS this Y-41.60% Inst Trans0.40% Short Ratio10.61 Perf Half Y-41.99%
Book/sh2.27 P/B3.88 EPS next Y14.80% ROA-38.20% Target Price- Perf Year-20.00%
Cash/sh3.73 P/C2.36 EPS next 5Y- ROE-45.20% 52W Range6.79 - 18.67 Perf YTD-44.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.53% Beta-
Dividend %- Quick Ratio27.50 Sales past 5Y- Gross Margin- 52W Low16.79% ATR1.30
Employees17 Current Ratio27.50 Sales Q/Q- Oper. Margin- RSI (14)33.34 Volatility13.24% 11.20%
OptionableNo Debt/Eq0.61 EPS Q/Q-30.80% Profit Margin- Rel Volume6.77 Prev Close8.80
ShortableYes LT Debt/Eq0.61 Earnings- Payout- Avg Volume78.27K Price7.93
Recom1.70 SMA20-32.63% SMA50-31.00% SMA200-39.12% Volume70,365 Change-9.89%
Jun-30-20Reiterated H.C. Wainwright Buy $24 → $18
Jun-24-20Initiated Northland Capital Outperform $21
Mar-24-20Initiated Needham Buy $20
Feb-21-19Initiated H.C. Wainwright Buy $20
Jul-14-20 07:00AM  
Jul-13-20 08:47AM  
Jul-09-20 11:01PM  
Jul-08-20 02:00PM  
Jul-07-20 04:29PM  
Jul-06-20 07:26PM  
Jul-02-20 11:00AM  
Jul-01-20 10:39PM  
Jun-30-20 06:00PM  
Jun-29-20 04:05PM  
Jun-12-20 10:00AM  
Jun-10-20 07:30AM  
May-27-20 05:19PM  
May-07-20 07:00AM  
May-06-20 07:05AM  
Apr-09-20 04:05PM  
Mar-13-20 07:00AM  
Mar-11-20 07:00AM  
Feb-20-20 09:45AM  
Jan-29-20 07:00AM  
Jan-18-20 10:00AM  
Jan-08-20 11:16AM  
Nov-28-19 10:43PM  
Nov-27-19 07:00AM  
Nov-25-19 07:00AM  
Nov-19-19 07:00AM  
Nov-06-19 04:05PM  
Nov-01-19 12:56PM  
Oct-18-19 07:00AM  
Oct-09-19 07:00AM  
Oct-07-19 07:00AM  
Sep-27-19 11:03AM  
Sep-24-19 09:17AM  
Sep-20-19 11:54AM  
Sep-18-19 09:31AM  
Sep-16-19 07:00AM  
Sep-11-19 10:13AM  
Aug-28-19 01:34PM  
Jun-27-19 04:01PM  
Jun-26-19 04:01PM  
May-28-19 09:41AM  
May-21-19 07:00AM  
May-07-19 04:01PM  
May-01-19 07:47AM  
Mar-07-19 04:01PM  
Mar-02-19 05:10PM  
Feb-27-19 07:00AM  
Feb-12-19 07:00AM  
Jan-07-19 07:00AM  
Jan-03-19 09:48AM  
Dec-20-18 10:39AM  
Nov-16-18 08:40AM  
Nov-07-18 04:32PM  
Nov-01-18 04:05PM  
Oct-18-18 10:52AM  
Sep-24-18 07:05AM  
Sep-13-18 08:42AM  
Sep-12-18 04:05PM  
Aug-15-18 06:50AM  
Aug-07-18 04:01PM  
Jul-10-18 04:23PM  
Jul-02-18 07:30AM  
Jun-28-18 11:00AM  
Jun-19-18 04:05PM  
Jun-15-18 06:28PM  
Jun-14-18 05:52PM  
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.